Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim- Vi®)

Vaccine

Volumn 17, Issue 23-24, 1999, Pages 2941-2945

  Kroon, Frank P ^a   Van Dissel, Jaap T ^a   Ravensbergen, Elisabeth ^a   Nibbering, Peter H ^a   Van Furth, Ralph ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HIV infection; Polysaccharide salmonella Vi antigen; Salmonella typhi

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; POLYSACCHARIDE VACCINE; TYPHOID VACCINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; SALMONELLOSIS; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION; VIRUS INFECTION;

ADULT; ANTIBODIES, BACTERIAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POLYSACCHARIDES, BACTERIAL; RNA, VIRAL; SALMONELLA TYPHI; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES;

EID: 0033529478     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00167-X     Document Type: Article

References (39)

1. Sperber S.J., Schleupner C.J. Salmonellosis during infection with human immunodeficiency virus. Rev Infect Dis. 9:1987;925-934.
2. Celum C.L., Chaisson R.E., Rutherford G.W., Barnhart J.L., Echenberg D.F. Incidence of Salmonellosis in patients with AIDS. J Infect Dis. 156:1987;992-998.
3. Jacobs J.L., Gold J.W.M., Murray H.W., Roberts R.B., Armstrong D. Salmonella infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 102:1985;186-188.
4. Glaser J.B., Morton-Kute L., Berger S.R., et al. Recurrent Salmonella typhimurium bacteremia associated with the acquired immunodeficiency syndrome. Ann Intern Med. 102:1985;189-193.
5. Smith P.D., Macher A.M., Bookman M.A., et al. Salmonella typhimurium enteritis and bacteremia in acquired immunodeficiency syndrome. Ann Intern Med. 102:1985;207-209.
6. Fischl M.A., Dickinson G.M., Sinave C., Pitchenik A.E., Cleary T.J. Salmonella bacteremia as manifestation of acquired immunodeficiency syndrome. Arch Intern Med. 146:1986;113-115.
7. Angulo F.J., Swerdlow D.L. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin Infect Dis. 21:1995;S84-S93.
8. Tumbarello M., Tacconelli E., Caponera S., Cauda R., Ortona L. The impact of bacteraemia on HIV infection. Nine years experience in a large Italian university hospital. J Infect. 31:1995;123-131.
9. Gotuzzo E., Frisancho O., Sanchez J., Liendo G., Carrillo C., Black R.E., Morris J.G. Jr. Association between the acquired immunodeficiency syndrome and infection with Salmonella typhi or Salmonella paratyphi in an endemic typhoid area. Arch Intern Med. 151:1991;381-382.
10. Centers for Disease Control, Prevention MMWR Morb Mortal Wkly Rep. p. 6, 43, 1994.
11. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering P, van Furth R, Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: five years follow up of antibody concentrations. Vaccine (in press).
12. Levine M.M., Herrington D., Murphy J.R., et al. Safety, infectivity. immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest. 79:1987;888-902.
13. Centers for Disease Control MMWR Morb Mortal Wkly Rep, 41, 1992.
14. Kroon F.P., van Furth R., Bruisten S.M. The effect of immunization in Human Immunodeficiency Virus type 1 infection. N Engl J Med. 335:1996;817-818.
15. Anderson J., Coutinho A., Lernhart W., Melchers F. Clonal growth and maturation to immunoglobulin secretion in vitro of every growth-inducible B lymphocyte. Cell. 10:1977;27-34.
16. Coutinho A. The theory of the one non-specific model for B-cell activation. Transplant Rev. 23:1975;49-65.
17. Lane H.C., Masur H., Edgar L.C., Whalen G., Rook A.H., Fauci A.S. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 309:1983;453-458.
18. Pahwa S.G., Quilop M.T.J., Lange M., Pahwa R.N., Grieco M.H. Defective B-lymphocyte function in homosexual men in relation to the acquired immunodeficiency syndrome. Ann Intern Med. 101:1984;757-763.
19. Ammann A.J., Schiffman G., Abrams D., Volberding P., Ziegler J., Conant M. B-cell immunodeficiency in the acquired immune deficiency syndrome. JAMA. 251:1984;1447-1449.
20. Mosier D.E., Subbarao B. Thymus-independent antigens: complexity of B-lymphocyte activation revealed. Immunology Today. 3:1982;217-222.
21. Mond J.J., Lees A., Snapper C.M. T cell-independent antigens type 2. Annu Rev Immunol. 13:1995;655-692.
22. Ballet J.J., Sulcebe G., Couderc L.J., et al. Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin Exp Immunol. 68:1987;479-487.
23. Ragni M.V., Ruben F.L., Winkelstein A., Spero J.A., Bontempo F.A., Lewis J.H. Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection. J Lab Clin Med. 109:1987;545-549.
24. Ochs H.D., Junker A.K., Collier A.C., Virant F.S., Handsfield H.H., Wedgewood R.J. Abnormal antibody responses in patients with persistent lymphadenopathy. J Clin Immunol. 8:1988;57-63.
25. Janoff E.N., Douglas J.M., Gabriel M., et al. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with the human immunodeficiency virus type 1. J Infect Dis. 158:1988;983-990.
26. Klein R.S., Selwyn P.A., Maude D., Pollard C., Freeman K., Schiffman G. Response to Pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus. J Infect Dis. 160:1989;826-831.
27. TM in HIV infected patients. [abstract]. VII Int Conf on AIDS, June 16-21, 1991, Florence, Italy, 1991. WB 2275.
28. Opravil M., Fierz W., Matter L., Blaser J., Luethy R. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol. 84:1991;185-189.
29. Rodriges-Barradas M.C., Musher D.M., Lahart C., et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent Pneumococcal vaccine. J Infect Dis. 165:1992;553-556.
30. Unsworth D.J., Rowen D., Carne C., Sonnex C., Baglin T., Brown D.L. Defective IgG2 response to Pneumovax in HIV seropositive patients. Genitourin Med. 69:1993;373-376.
31. Loeliger A.E., Rijkers G.T., Aerts P., Been-Tiktak A., Hoepelman A.I., van Dijk H., Borleffs J.C. Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients. FEMS Immunology and Medical Microbiology. 12:1995;33-41.
32. Stein K.E. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 165:1992;S49-52.
33. Keitel W.A., Bond N.L., Zahradnik J.M., Cramton T.A., Robbins J.B. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine. 12:1994;195-199.
34. Webster M.E., Landy M., Freeman M.E. Sudies on Vi antigen; II Purification of Vi antigen from Escherichia coli 5396/38. J Immunol. 69:1952;135-142.
35. Szewczyk B., Taylor A. Purification and immunochemical properties of Escherichia coli B polysaccharide cross-reacting with Salmonella typhi Vi antigen: preliminary evidence for cross-reaction of the polysaccharide with Escherichia coli K1 antigen. Infect Immun. 41:1983;224-231.
36. Eriksson K., Kilander A., Hagberg L., Norkrans G., Holmgren J., Czerkinsky C. Intestinal antibody responses to oral vaccination in HIV-infected individuals. AIDS. 3:1993;1087-1091.
37. Klugman K.P., Koornhof H.J., Schneerson, Cadoz M., Gilbertson I.T., Robbins J.B., Schulz D., Arman J. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. ii:1987;1165-1169.
38. Acharya I.L., Lowe C.U., Thapa R., et al. Prevention of thypoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. N Engl J Med. 317:1987;1101-1104.
39. Klugman K.P., Koornhof H.J., Robbins J.B., Le Cam N.N. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. 14:1996;435-438.